These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28332450)

  • 1. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
    Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
    Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?
    Briganti V; Cuccurullo V; Di Stasio GD; Mansi L
    Curr Radiopharm; 2019; 12(2):156-170. PubMed ID: 30827276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
    Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Bal CS; Gupta SK; Zaknun JJ
    Trop Gastroenterol; 2010; 31(2):87-95. PubMed ID: 20862981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
    Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Briganti V; Cuccurullo V; Berti V; Di Stasio GD; Linguanti F; Mungai F; Mansi L
    Curr Radiopharm; 2020; 13(3):166-176. PubMed ID: 31886756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear medicine imaging of neuroendocrine tumours.
    Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
    Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
    Cuccurullo V; Di Stasio GD; Mansi L
    Curr Radiopharm; 2019; 12(2):98-106. PubMed ID: 30727940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide imaging with somatostatin analogues: more than cancer probes.
    Cascini GL; Cuccurullo V; Tamburrini O; Rotondo A; Mansi L
    Curr Radiopharm; 2013 Mar; 6(1):36-40. PubMed ID: 23470033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
    Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
    Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
    Ambrosini V; Tomassetti P; Rubello D; Campana D; Nanni C; Castellucci P; Farsad M; Montini G; Al-Nahhas A; Franchi R; Fanti S
    Nucl Med Commun; 2007 Jun; 28(6):473-7. PubMed ID: 17460538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The present and future role of (111)In pentetreotide in the PET era.
    Rambaldi PF; Cuccurullo V; Briganti V; Mansi L
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):225-35. PubMed ID: 16172568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
    Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA
    Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
    Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?
    Santhanam P; Chandramahanti S; Kroiss A; Yu R; Ruszniewski P; Kumar R; Taïeb D
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1144-55. PubMed ID: 25771906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
    Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
    J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary nuclear medicine imaging of neuroendocrine tumours.
    Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
    Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.